It is made available under a CC-BY-NC-ND 4.0 International license .

1	Rapid Detection of SARS-CoV-2 Antigen from Serum in a Hospitalized Population
2	McAulay K, Kaleta EJ, Grys TE*
3	
4	Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix AZ
5	
6	*Correspondence to: Thomas.Grys@mayo.edu
7	
8	Abstract
9	SARS-CoV-2 viremia has been demonstrated in some patients using molecular assays.
10	Here we demonstrate detection of SARS-CoV-2 antigen in a cohort of hospitalized
11	patients using a rapid diagnostic test from Anhui Deepblue Medical Technology Co.,
12	Ltd. We detected antigen in serum from 11 of 13 patients at time points ranging from
13	three to eighteen days from symptom onset and observed that the disappearance of an
14	antigen signal was associated with seroconversion. These results demonstrate proof of
15	principle use of a rapid antigen test with serum samples in a format compatible with
16	point of care testing.

It is made available under a CC-BY-NC-ND 4.0 International license .

17 Introduction

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute 18 respiratory syndrome virus 2 (SARS-CoV-2), has placed tremendous strain on 19 centralized clinical laboratories due to high volumes of testing and supply chain 20 challenges. Rapid diagnostic tests (RDT) present an opportunity to reduce the burden 21 on centralized testing labs. Many RDT are lateral flow devices which, with appropriate 22 validation, can easily be performed in a point of care (POC) setting. There are a large 23 number of these tests currently approved by the FDA for antibody detection and the 24 market for rapid antigen detection from respiratory specimens is currently expanding. 25 While concerns remain regarding clinical accuracy[1, 2], these tests are changing the 26 response to the pandemic since the results can be available in as little as 10-20 minutes 27 after specimen collection. This compares favorably to the current gold standard 28 molecular methods, for which laboratory turn-around times for high-throughput batch 29 testing are typically 6-8 hours or more, and when there is a surge of disease or shortage 30 of supplies, actual turn-around may take days. 31 SARS-CoV-2 is known to reach high levels of detectable RNA in the 32 33 nasopharynx. While there have been several reports of measurable viremia in

hospitalized patients, these investigations have focused on nucleic acid detection[3, 4];

there are few peer-reviewed reports of SARS-CoV-2 antigenemia[5, 6]. Since some viral

³⁶ proteins are present in multiple copies per virion, we tested whether a rapid antigen kit

could detect antigenemia in patients who had been diagnosed with COVID-19.

38

39 Methods

It is made available under a CC-BY-NC-ND 4.0 International license .

40 Clinical Specimens

Residual serum was obtained from 54 standard of care specimens from 13
SARS-CoV-2 PCR-positive, hospitalized patients at Mayo Clinic Arizona and stored at 80 °C until further use. The serum reflected samples collected from 2 to 24 days after
onset of symptoms. Use of these specimens was reviewed and approved by the Mayo
Clinic Institutional Review Board under protocol # 20-004544.

46

47 Antibody Tests

Antibody tests were performed using the SARS-CoV-2 IgG/IgM Rapid Test
(ACON Laboratories Inc.) according to the manufacturer's instructions. Briefly, 5 µL
serum was applied to the sample well, followed by 2-3 drops of buffer. Tests were
incubated on a flat surface and read after 15 minutes. Results were recorded in a binary
fashion as either positive or negative, with IgM alone, IgG alone, or IgM + IgG all being
recorded as "positive".

54

55 Antigen Tests

Antigen tests were performed using COVID-19 (SARS-CoV-2) Antigen Test Kit
(Colloidal Gold) (Anhui Deepblue Medical Technology Co., Ltd.) using the same
process described above for antibody tests. i.e. 5 µL serum was applied to the sample
well, followed by 2-3 drops of buffer. Tests were incubated on a flat surface and read
after 15 minutes.

61

62 Results & Discussion

It is made available under a CC-BY-NC-ND 4.0 International license .

63	Serum from 13 hospitalized SARS-CoV-2 RT-PCR-positive patients at Mayo
64	Clinic Arizona were tested for SARS-CoV-2 antigen and antibody using COVID-19
65	(SARS-CoV-2) Antigen Test Kit (Colloidal Gold) (Anhui Deepblue Medical Technology
66	Co., Ltd.) and SARS-CoV-2 IgG/IgM Rapid Test (ACON Laboratories Inc.), respectively.
67	Specimens spanned 2-24 days from the onset of symptoms with a minimum of two and
68	a maximum of eight time points per patient ($n = 54$). For 12 of the 13 patients tested
69	(51/54 specimens), serum was always positive for either antigen, antibody, or both, and
70	disappearance of antigen was always associated with the presence of antibody. The
71	latest antigen detection occurred 18 days after symptom onset and the earliest antibody
72	detection occurred six days after symptom onset.

The potential to offer serology testing in a POC setting, such as a drive-through, 73 provides an opportunity to avoid centralized phlebotomy, thus minimizing the risk of 74 exposure for patients. However, what is particularly striking here is detection of SARS-75 CoV-2 antigen in the serum of 11 of 13 individuals using an assay designed for 76 77 pharyngeal and nasopharyngeal specimens. While a small number of studies have described detectable SARS-CoV-2 antigenemia [5,6], to our knowledge this is the first 78 such report using rapid tests with the potential to be used in a POC setting. The authors 79 recognize that these findings must be validated using a larger sample size and including 80 non-hospitalized individuals with mild or asymptomatic infection to verify the sensitivity 81 82 of antigen detection in serum. Nonetheless, an opportunity to rapidly detect COVID-19 infection status at the POC, without respiratory specimen collection, is promising. 83 Further, detectable antigenemia may be a useful prognostic indicator for disease acuity 84

4

It is made available under a CC-BY-NC-ND 4.0 International license .

85	in hospitalized patients a	nd may potentially be used to demonstrate response to											
86	therapies; this novel appl	ication therefore warrants further study.											
87													
88	Acknowledgements												
89	The authors wish to than	e authors wish to thank Paramount Labs for providing the Anhui DeepBlue kits and											
90	ACON Laboratories for p	ON Laboratories for providing the antibody kits. We also recognize salary support for											
91	KM and TG and from the	and TG and from the Mayo Clinic Center for Individualized Medicine.											
92													
93	References												
94	1. Centers for Diseas	se Control and Prevention. 11/05/2020: FDA Lab Alert: FDA											
95	Issues Safety Lette	er about Potential for False Positive Results with Antigen Tests											
96	for Rapid Detectio	n of SARS-CoV-2. 2020.											
97	https://www.cdc.go	ov/csels/dls/locs/2020/fda_issues_safety_letter_about_false_p											
98	ositive_results_wit	h_antigen_tests_for_rapid_detection_of_sars-cov-2.html											
99	[Accessed 12/13/2	2020]											
100	2. Pettengill MA, McA	Adam AJ. 2020. Can We Test Our Way Out of the COVID-19											
101	Pandemic? J Clin	Microbiol Oct 21;58(11):e02225-20. doi:											
102	https://doi.org/10.1	<u>128/JCM.02225-20</u> .											
103	3. Hagman K, Heder	istierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner J,											
104	Ursing J. 2020. SA	ARS-CoV-2 RNA in serum as predictor of severe outcome in											
105	COVID-19: a retro	spective cohort study. Clin Infect Dis. Aug 28:ciaa1285. doi:											
106	https://doi.org/10.1	093/cid/ciaa1285. Epub ahead of print.											

It is made available under a CC-BY-NC-ND 4.0 International license .

- 4. Nijhuis RHT, Russcher A, de Jong GJ, Jong E, Herder GJM, Remijn JA, Verweij
- 108 SP. 2020. Low prevalence of SARS-CoV-2 in plasma of COVID-19 patients
- presenting to the emergency department. J Clin Virol Dec;133:104655. doi:
- 110 <u>https://doi.org/10.1016/j.jcv.2020.104655</u>. Epub 2020 Oct 5
- 5. Le Hingrat Q, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y,
- 112 Duval X, Ichou H, Damond F, Bertine M, Benmalek N, French COVID cohort
- 113 management committee, CoV-CONTACT study group, Choquet C, Timsit J-F,
- 114 Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N. 2020. SARS-CoV-2 N-
- antigenemia: A new alternative to nucleic acid amplification techniques. medRxiv
- 116 2020.09.14.20191759; doi: <u>https://doi.org/10.1101/2020.09.14.20191759</u>
- 6. Su B, Yin J, Lin X, Zhang T, Yao X, Xu Y, Lu Y, Wang W, Liu K, Zhang J, Xie L,
- Jin R, Feng Y. 2020. Quantification of SARS-CoV-2 antigen levels in the blood of
- patients with COVID-19. Sci China Life Sci Nov 26:1–4. doi:
- 120 https://doi.org/10.1007/s11427-020-1830-8. Epub ahead of print

Subject ID	Test	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
T901	Ag					-																			
1301	Ab					-			-		-														
TS02	Ag									+			+	-											
1302	Ab									-			+	+				+							
T903	Ag							+			+					-									
1000	Ab							-			-					+		+							
TS04	Ag											+			-										
1004	Ab									_		-			+										
TS05	Ag									+					-										
1000	Ab									+		-			+				+						
TS06	Ag										+	+				-	-			-					
1000	Ab				-			-	-	-	-	-				+	+			+					
TS07	Ag				+			-	-	-		-					-				-			-	
1007	Ab				-			+	+	+		+				-	+				+			+	
TS08	Ag															+	+		+		-				
	Ab															-	-		+		+				
TS09	Ag										-		-			-	-								
	Ab			-					-		+		+			+	+						_		
TS10	Ag			+					+		+					+		+				-			
	Ab			-					-		-					-		+				+			
TS11	Ag						+		-	-	-														
	Ab						+		+	+	+														
TS12	Ag															+		+							-
	Ab											_				+		+							+
TS13	Ag							+	+		-					-				-					
1010	Ab							+	+		+					+				+					

Days Since Diagnosis

Table 1. Serum antigen (Ag) and antibody (Ab) results for 13 SARS-CoV-2 PCR-positive, hospitalized individuals as determined by COVID-19 (SARS-CoV-2) Antigen Test Kit (Colloidal Gold) (Anhui Deepblue Medical Technology Co., Ltd.) and SARS-CoV-2 IgG/IgM Rapid Test (ACON Laboratories Inc.), respectively.

It is made available under a CC-BY-NC-ND 4.0 International license

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1. Serum antigen and antibody results for subject TS06 determined by COVID-

19 (SARS-CoV-2) Antigen Test Kit (Colloidal Gold) (Anhui Deepblue Medical

Technology Co., Ltd.) and SARS-CoV-2 IgG/IgM Rapid Test (ACON Laboratories Inc.),

respectively at 10, 11, 15, 16, and 19 days after symptom onset.